摘要
结直肠癌(CRC)作为世界上第三大常见癌症,起源于结肠和直肠的肠上皮细胞,随着全球经济的快速发展,其在发展中国家的发病率也逐年猛增。在过去几年中,尽管预防性的结肠镜筛查提高了CRC患者生存率,但仍有大多数病例是在症状出现后才被发现,且目前临床中CRC手术治疗风险高、易复发,放化疗治疗不良反应大、患者心理负担重,因而针对CRC尚无理想的诊疗方案。磷脂酰肌醇3-激酶/蛋白激酶B(PI3K/Akt)作为经典的致癌通路为多种恶性疾病的诊疗提供了可能,也为CRC的治疗提供了新的方向。近年来,中医凭借自身“治未病”和多成分、多靶点、多途径的优势在癌症治疗中成为一大焦点,其不良反应小的优势更是与西医在治疗上相互弥补。多项研究表明,中药单体和中药复方可通过干预PI3K/Akt信号通路,可抑制CRC细胞的增殖、侵袭、迁徙、血管新生,促进了癌细胞的凋亡、自噬,从而减缓CRC发展进程,达到治疗CRC的作用。近几年与此相关的研究成果更新迅速,过去的总结文献未能及时纳入最新研究成果,为众多学者的文献检索带来诸多不便,故而该文从PI3K/Akt通路、PI3K/Akt通路与CRC关联性及中医药干预治疗CRC进展等3个方面出发,对相关信息进行补充总结,以期为今后CRC在分子生物学中的发展及临床新药研发上提供参考。
Colorectal cancer(CRC),as the third most common cancer in the world,develops from the colonic and rectal epithelial cells.With the rapid development of the global economy,the incidence of CRC in developing countries has been increasing year by year.In the past few years,although preventive colonoscopy screening has improved the survival rate of CRC patients,the majority of cases are still detected after symptoms appear.Currently,the clinical treatment of CRC carries high surgical risks and is prone to recurrence,while radiotherapy and chemotherapy have significant side effects and cause a heavy psychological burden on patients.Therefore,there is currently no ideal treatment protocol for CRC.The phosphatidylinositol 3-kinase/protein kinase B(PI3K/Akt)pathway,as a classical oncogenic pathway,provides potential for the diagnosis and treatment of various malignant diseases,and offers a new direction for the treatment of CRC.In recent years,traditional Chinese medicine(TCM)has become a major focus in cancer treatment due to its advantages in"preventing and treating diseases"and its multiple components,targets,and pathways.Its advantages in having fewer side effect complement western medicine in treatment.Multiple studies have shown that Chinese medicinal monomers and compound formulas can inhibit the proliferation,invasion,migration,and angiogenesis of CRC cells,promote apoptosis and autophagy of cancer cells,and slow down the development of CRC by intervening in the PI3K/Akt signaling pathway,thereby achieving the therapeutic effect on CRC.In recent years,the research progress related to this has been updating rapidly.Previous literature failed to timely incorporate the latest research results,which brought many inconveniences to the literature search of many scholars.Therefore,this article summarized the relevant information from PI3K/Akt pathway,the association between the PI3K/Akt pathway and CRC,and the progress of TCM intervention in the treatment of CRC to provide references for the development of CRC in molecular biology and the clinical development of new drugs in the future.
作者
李华
王捷虹
LI Hua;WANG Jiehong(Shaanxi University of Chinese Medicine,Xianyang 712000,China;Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2023年第13期254-263,共10页
Chinese Journal of Experimental Traditional Medical Formulae
基金
陕西省中医药管理局中医药防治消化道癌前病变重点研究室项目(陕中医药发[2019]9号)
陕西中医药大学附属医院科研课题(2020XZ001)。
